Henry Q Xiong

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Epidermal growth factor receptor-targeted therapy for pancreatic cancer
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 29:31-7. 2002
  2. ncbi request reprint Molecular targeting therapy for pancreatic cancer
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, Unit 426, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:S69-77. 2004
  3. ncbi request reprint Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2066-71. 2003
  4. ncbi request reprint Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions
    Henry Q Xiong
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 66:1059-72. 2006
  5. ncbi request reprint Treatment of colorectal cancer metastasis: the role of chemotherapy
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Metastasis Rev 23:145-63. 2004
  6. ncbi request reprint Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1145-51. 2006
  7. ncbi request reprint Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1035-46. 2006
  8. ncbi request reprint Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity
    Daoyan Wei
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 64:2030-8. 2004
  9. ncbi request reprint Novel therapies for pancreatic adenocarcinoma
    Simona M Pino
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Gastroenterol Rep 6:119-25. 2004
  10. doi request reprint Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
    Henry Q Xiong
    Center for Cancer and Blood Disorders, Fort Worth, Texas, USA
    Cancer 113:2046-52. 2008

Detail Information

Publications27

  1. ncbi request reprint Epidermal growth factor receptor-targeted therapy for pancreatic cancer
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Semin Oncol 29:31-7. 2002
    ..A phase II trial of the EGFR inhibitor IMC-C225 in combination with gemcitabine for patients with advanced pancreatic cancer is discussed...
  2. ncbi request reprint Molecular targeting therapy for pancreatic cancer
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, Unit 426, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:S69-77. 2004
    ..This review highlights recent advances in the development of these agents...
  3. ncbi request reprint Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2066-71. 2003
    ..o. This Phase I trial was conducted to determine the toxicity profile, maximal tolerated dose, and pharmacokinetics profile, including bioavailability, of p.o. 9-ACCD in patients with advanced solid tumors...
  4. ncbi request reprint Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions
    Henry Q Xiong
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 66:1059-72. 2006
    ..The search for effective therapy for advanced pancreatic cancer continues. Gemcitabine in combination with cytotoxic agents or molecular targeted agents hold promise...
  5. ncbi request reprint Treatment of colorectal cancer metastasis: the role of chemotherapy
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Metastasis Rev 23:145-63. 2004
    ..Optimal combinations and sequences of treatment are being studied, since several effective regimens have become available...
  6. ncbi request reprint Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1145-51. 2006
    ..To study the safety of bevacizumab with capecitabine-based chemoradiotherapy...
  7. ncbi request reprint Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1035-46. 2006
    ....
  8. ncbi request reprint Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity
    Daoyan Wei
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 64:2030-8. 2004
    ..Collectively, our data provide a novel molecular mechanism for the antitumor activity of celecoxib and may help further improve its effectiveness in controlling pancreatic cancer growth and metastasis...
  9. ncbi request reprint Novel therapies for pancreatic adenocarcinoma
    Simona M Pino
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Gastroenterol Rep 6:119-25. 2004
    ..The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed...
  10. doi request reprint Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
    Henry Q Xiong
    Center for Cancer and Blood Disorders, Fort Worth, Texas, USA
    Cancer 113:2046-52. 2008
    ..A phase 2 trial was conducted to explore the efficacy of capecitabine and oxaliplatin (XELOX) in patients with advanced pancreatic cancer previously who were treated with gemcitabine...
  11. ncbi request reprint NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Cancer 108:181-8. 2004
    ..Collectively, these data suggest that suppression of tumorigenicity and metastasis by NF-kappaB blockade is due to impaired angiogenic potential of tumor cells...
  12. ncbi request reprint Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas
    Adrian A Wong
    The University of Texas Medical School at San Antonio, San Antonio, Texas, USA
    Am J Clin Oncol 28:227-33. 2005
    ....
  13. ncbi request reprint Adjuvant therapy for pancreatic cancer: current status and future directions
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Surg Oncol Clin N Am 13:737-49, xi. 2004
    ..The recent developments in the fields of radiosensitization, chemotherapy, and molecular-targeted therapy are outlined. Finally, the future study strategies for adjuvant therapy trials are discussed...
  14. ncbi request reprint A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 55:559-64. 2005
    ..To evaluate whether celecoxib alters the conversion of gemcitabine into its active metabolite, difluorodeoxycytidine triphosphate (dFdCTP), in peripheral blood mononuclear cells (PBMCs)...
  15. ncbi request reprint Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668
    Darren W Davis
    Department of Cancer Biology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:678-89. 2005
    ....
  16. ncbi request reprint Novel therapies for pancreatic adenocarcinoma
    Simona M Pino
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 6:199-206. 2004
    ..The scientific rationale, mechanism of action, and clinical trial data for these novel agents are discussed...
  17. pmc Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation
    Cielito C Reyes-Gibby
    Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Pain Symptom Manage 34:244-52. 2007
    ..This study demonstrates the feasibility and usefulness of symptom assessment in chemoradiation protocols. Future studies with larger cohorts are needed to further characterize multiple symptoms associated with chemoradiation...
  18. ncbi request reprint Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2610-6. 2004
    ....
  19. ncbi request reprint Experimental animal models of pancreatic carcinogenesis and metastasis
    Daoyan Wei
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Gastrointest Cancer 33:43-60. 2003
    ..The advantages and disadvantages of each model and their clinical implications are discussed, and special attention is focused on experimental therapeutic strategies targeting pancreatic cancer metastasis...
  20. ncbi request reprint Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases
    Jean Nicolas Vauthey
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:2065-72. 2006
    ..Chemotherapy before resection of hepatic colorectal metastases (CRM) may cause hepatic injury and affect postoperative outcome...
  21. ncbi request reprint A phase I surrogate endpoint study of SU6668 in patients with solid tumors
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology, University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Invest New Drugs 22:459-66. 2004
    ..To evaluate the biologic effects of SU6668 in patients with solid tumors using comprehensive measures of pharmacokinetics (PK), functional imaging, and tissue correlative studies...
  22. ncbi request reprint Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis
    Daoyan Wei
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Oncogene 22:319-29. 2003
    ..These results indicate that Stat3 directly regulates VEGF expression and hence angiogenesis, growth, and metastasis of human pancreatic cancer, suggesting that Stat3 signaling may be targeted for treatment of pancreatic cancer...
  23. ncbi request reprint Chemoradiation for resectable gastric cancer
    Henry Q Xiong
    Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, TX 77030, USA
    Lancet Oncol 4:498-505. 2003
    ..Preoperative chemotherapy or chemoradiation has been accepted to have a theoretical advantage over postoperative therapy and has now been shown to be a feasible option. Its efficacy, however, remains to be tested...
  24. ncbi request reprint Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines
    Maria S Pino
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Cancer Res 66:3802-12. 2006
    ..Quantification of TGF-alpha expression may therefore represent an effective means of identifying EGFR-responsive primary tumors...
  25. ncbi request reprint Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
    Mark J Ratain
    University of Chicago, Chicago, IL 60637, USA
    J Clin Oncol 24:2505-12. 2006
    ..This phase II randomized discontinuation trial evaluated the effects of sorafenib (BAY 43-9006), an oral multikinase inhibitor targeting the tumor and vasculature, on tumor growth in patients with metastatic renal cell carcinoma...
  26. ncbi request reprint Report of the 16th International Symposium of the Foundation for Promotion of Cancer Research: Recent advances in pancreatic cancer
    Henry Q Xiong
    University of Texas, M D Anderson Cancer Center, TX, USA
    Jpn J Clin Oncol 33:246-53. 2003
  27. ncbi request reprint Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells
    Maria S Pino
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome Italy
    Cancer Biol Ther 4:1263-9. 2005
    ..Understanding the pathways that control COX-2 expression may lead to a better understanding of its dysregulation in pancreatic carcinomas and facilitate the development of novel therapeutic approaches...